期刊文献+

Research progress in nanoparticles as anticancer drug carrier 被引量:1

纳米粒作为抗肿瘤药物载体的研究进展(英文)
下载PDF
导出
摘要 Nanoparticles drug delivery system has sustained and controlled release features as well as targeted drug delivery, which can change the characteristics of drug distribution in vivo. It can increase the stability of the drug and enhance drug bioavailability. The selective targeting of nanoparticles can be achieved through enhanced permeability and retention effect and a conjugated specific ligand or through the effects of physiological conditions, such as pH and temperature. Nanoparticles can be prepared by using a wide range of materials and can be used to encapsulate chemotherapeutic agents to reduce toxicity, which can be used for imaging, therapy, and diagnosis. In this research, recent progress on nanoparticles as a targeted drug delivery system will be reviewed, including positive-targeting, negative-targeting, and physicochemical-targeting used as anticancer drug carriers.
出处 《The Chinese-German Journal of Clinical Oncology》 CAS 2014年第10期489-493,共5页 中德临床肿瘤学杂志(英文版)
基金 Supported by a grant from the foundation of Guangzhou Municipal Key Project for Special Scientific Plan(No.2008A1-E4101)
关键词 NANOPARTICLES anticancer drugs drug carrier 药物载体 纳米粒子 抗癌 靶向给药系统 纳米颗粒 生物利用度 生理条件 稳定性
  • 相关文献

参考文献6

二级参考文献42

  • 1郑秀海,董家鸿,李前伟,喻智勇,王曙光.放射性碘标记人工合成RGD肽拮抗物的设计与分子特性的计算机分析与模拟研究[J].第三军医大学学报,2005,27(4):340-342. 被引量:1
  • 2张晓佳,夏强,马全红,段磊,顾宁.高压均质法制备载有维甲酸的纳米结构脂质载体[J].过程工程学报,2005,5(1):54-57. 被引量:7
  • 3刘广元,李前伟,黄定德,刘开元,谢来平,陈杰,罗朝学.^(99)Tc^m-RGD-4CK在动物体内的分布及显像[J].中华核医学杂志,2007,27(1):34-37. 被引量:5
  • 4[1]KIRCHNER EM,GERHARDS R,VOIGTMANN R.Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer:reduction of 17-1A-positive disseminated tumour cells[J].Ann Oncol,2002,13(7):1044-1048. 被引量:1
  • 5[2]ARTEAGA CL.Trastuzumab,an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer[J].Breast Cancer Res,2003,5(2):96-100. 被引量:1
  • 6[3]MONTSERRAT E.Rituximab in chronic lymphocytic leukemia[J].Semin Oncol,2003,30(1 Suppl 2):34-39. 被引量:1
  • 7[4]CZUCZMAN MS,GRILLO-LOPEZ AJ,WHITE CA,et al.Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy[J].J Clin Oncol,1999,17(1):268-276. 被引量:1
  • 8[5]VOSE JM,LINK BK,GROSSBARD ML,et al.Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated,aggressive non-Hodgkin's lymphoma[J].J Clin Oncol,2001,19(2):389-397. 被引量:1
  • 9[6]SLAMON DJ,LEYLAND-JONES B,SHAK S,et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2[J].N Engl J Med,2001,344(11):783-792. 被引量:1
  • 10[7]PEGRAM MD,LOPEZ A,KONECNY G,et al.Trastuzumab and chemotherapeutics:drug interactions and synergies[J].Semin Oncol,2000,27(6 Suppl 11):21-25. 被引量:1

共引文献31

同被引文献6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部